MedTrace Logo

A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia

NCT04016636 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-02-16

No results posted yet for this study

Summary

The aim of this study is to evaluate the impact of Ibrutinib monotherapy in the QoL of subjects with Chronic Lymphocytic Leukemia (CLL) based in European Quality of Life 5 Dimensions (EQ-5D) and FACIT- fatigue questionnaires assessment from baseline to 1 year of treatment in Argentinian routine clinical practice.

Conditions

Interventions

OTHER

Standard of Care

Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 12 months.

Sponsors & Collaborators

  • Janssen-Cilag Ltd.

    collaborator INDUSTRY

  • Mela Osorio Maria Jose

    lead OTHER

Principal Investigators

  • Maria Jose Mela, MD · Fundaleu

  • Miguel A Pavlovsky, MD · Fundaleu

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-12
Primary Completion
2021-08-30
Completion
2022-10-15

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04016636 on ClinicalTrials.gov